N2:MRCH

Drugmaker AbbVie expects Humira volume erosion to worsen

By Leroy Leo and Christy Santhosh (Reuters) -AbbVie expects a drop in sales volumes of...

N2:BLR N2:CMPNY N2:HOT N2:IMMOGY N2:JUDIC N2:MRCH N2:MRCH1 N2:NAMER N2:PHMR N2:PUBL N2:SCI N2:SOFW N2:STX N2:US N2:VACCIN

Moderna shares fall after judge sides with Arbutus in patent fight

(Reuters) -Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order...

N2:BIOPH N2:CMPNY N2:HEA N2:HECA N2:MRCH N2:MTPIX N2:NAMER N2:PHAR N2:PHMR N2:PUBL N2:PXP N2:RES N2:RESF N2:US

Biogen sees flat 2024 sales, pick up in Alzheimer’s drug demand

By Manas Mishra and Sriparna Roy (Reuters) -Biogen on Tuesday forecast flat 2024 product revenue...

N2:BIODRG N2:BLR N2:CMPNY N2:DEAL1 N2:MRCH N2:MRG N2:NAMER N2:PHAG08 N2:PHAR1 N2:PHMR N2:PUBL N2:US

Gilead to buy CymaBay for $4.3 billion in bets on liver disease treatment

By Bhanvi Satija (Reuters) -Gilead Sciences has agreed to buy CymaBay Therapeutics for $4.3 billion,...

N2:BACT N2:BIZ N2:BLR N2:CMPNY N2:FINE1 N2:HEA N2:HECA N2:IPO N2:ISU N2:LIST1 N2:MRCH N2:MRCH1 N2:NAMER N2:PUBL N2:STK N2:STX N2:US

Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut

(Reuters) – Shares of Metagenomi Technologies, a genetic medicines company backed by Bayer Healthcare and...

N2:BIODRG N2:BLR N2:CMPNY N2:COVID N2:DE N2:EUROP N2:HEA N2:HECA N2:HFAC N2:HFAC1 N2:INFDIS N2:MRCH N2:MRCH1 N2:MTPIX N2:NAMER N2:NEWS1 N2:PHAG08 N2:PHAR1 N2:PHMR N2:PUBHEA N2:PUBL N2:PXP N2:RES N2:RESF N2:RESPIR N2:US N2:VACCIN

Pfizer posts surprise 4th quarter profit, but key products miss on sales

By Michael Erman and Bhanvi Satija (Reuters) -Pfizer reported a surprise quarterly profit on Tuesday,...

N2:ASIA N2:BE N2:BIOPH N2:BL N2:CMPNY N2:CPROD N2:EREP N2:EUROP N2:EXCLSV N2:FR N2:GB N2:HEA N2:JP N2:MEVN N2:MRCH N2:MTPIX N2:NAMER N2:NEWS1 N2:PHAG08 N2:PHAR1 N2:PHMR N2:PUBL N2:PXP N2:TOPNWS N2:US

Exclusive-Drugmakers set to raise U.S. prices on at least 500 drugs in January

By Michael Erman and Patrick Wingrove NEW YORK (Reuters) -Drugmakers including Pfizer, Sanofi and Takeda...

N2:BLR N2:CMPNY N2:CNCER N2:DRUDEV N2:DVST N2:HEA N2:HECA N2:MRCH N2:MRCH1 N2:MTPIX N2:NAMER N2:PHAG08 N2:PHAR1 N2:PHMR N2:PUBL N2:PXP N2:RES N2:RESF N2:US

Johnson & Johnson forecasts as much as 6% sales growth in 2024

By Patrick Wingrove and Bhanvi Satija (Reuters) -Johnson & Johnson on Tuesday forecast revenue growth...

N2:BIODRG N2:BLR N2:CMPNY N2:COMDIS N2:COVID N2:DE N2:EUROP N2:HEA N2:HECA N2:INFDIS N2:MRCH N2:MRCH1 N2:MTPIX N2:NAMER N2:NEWS1 N2:PHAG08 N2:PHAR1 N2:PUBHEA N2:PUBL N2:PXP N2:RES N2:RESF N2:US N2:VACCIN

Pfizer looks beyond COVID after quarterly loss on Paxlovid charge

By Bhanvi Satija and Michael Erman (Reuters) – Pfizer on Tuesday urged investors to focus...

N2:BIODRG N2:CMPNY N2:COVID N2:DE N2:EUROP N2:HEA N2:HECA N2:HFAC N2:HFAC1 N2:INSR N2:MRCH N2:MRCH1 N2:MTPIX N2:NAMER N2:NEWS1 N2:PHAG08 N2:PHAR1 N2:PHARWH N2:PUBHEA N2:PUBL N2:RDRU N2:RDRU1 N2:US N2:VACCIN

New COVID shots still hard to find for some Americans

By Michael Erman and Ahmed Aboulenein NEW YORK/WASHINGTON (Reuters) – Americans have started rolling up...

Breaking

Drugmaker AbbVie expects Humira volume erosion to worsen

Moderna shares fall after judge sides with Arbutus in patent fight

Biogen sees flat 2024 sales, pick up in Alzheimer’s drug demand

Gilead to buy CymaBay for $4.3 billion in bets on liver disease treatment

Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut

Pfizer posts surprise 4th quarter profit, but key products miss on sales

Exclusive-Drugmakers set to raise U.S. prices on at least 500 drugs in January

Johnson & Johnson forecasts as much as 6% sales growth in 2024

Pfizer looks beyond COVID after quarterly loss on Paxlovid charge

New COVID shots still hard to find for some Americans

You Missed

China’s property sector is showing positive changes, minister says

Doctors push back as parents embrace Kennedy and vitamin A in Texas measles outbreak

US Secret Service shoots armed man near White House overnight, agency says

Virgin Group aims to raise $900 million for rail service bid, company says

Live Market Pulse

Recent Posts

Recent Comments